Search
Returning search results with filters:
Remove filter for
Audience: Health professionals
Remove filter for
Issue: Health products
Remove filter for
Recall class: Type I
Clear all
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 141 items.
Affected lot may contain the presence of particles
RecallHealth product recall | 2022-08-29
Pharmascience Inc. is recalling one lot of pms-Hydromorphone, 2 mg tablets, (lot 639268) as the bottles may contain hydromorphone tablets of a different strength (8 mg), meaning they contain higher amounts of hydromorphone. Products from the affected lot…
RecallHealth product recall | 2022-08-22
The affected lots may contain glass particles.
RecallHealth product recall | 2022-08-02
Presence of Gluconacetobacter liquefaciens in affected lots.
RecallHealth product recall | 2022-07-25
All lots contain an undeclared ingredient (sildenafil) that is listed on the prescription drug list.
RecallHealth product recall | 2022-06-01
Intravenous bag may be leaking in affected lot
RecallHealth product recall | 2022-03-07
Solution bags may be leaking in affected lot.
RecallHealth product recall | 2022-02-28
Affected lots exceeds concentration limit for N-nitrosodimethylamine (NDMA) at the 36-month stability testing timepoint.
RecallHealth product recall | 2022-01-26
Affected lot exceeds concentration limit for N-nitrosodimethylamine (NDMA) at the 36-month stability testing timepoint.
RecallHealth product recall | 2022-01-26
Visible particles observed in vials following reconstitution
RecallHealth product recall | 2022-01-17
Presence of N-nitrosodimethylamine (NDMA) above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2021-12-03
Affected lot may contain the presence of particles
RecallHealth product recall | 2021-11-30
Product sterility may be compromised in the affected lot due to the possibility of defects in the vial.
RecallHealth product recall | 2021-11-22
Presence of impurity Losartan Azide ((5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole)) above the acceptable concentration limit in affected lots.
RecallHealth product recall | 2021-10-25
Sivem Pharmaceuticals Losartan HCT product recall (2021-10-13)
Starting date:
October 13, 2021
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:…
RecallHealth product recall | 2021-10-13